Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 5, 2026, 5:25 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 6,408 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Bone Diseases Clear all
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Study of Romosozumab (AMG 785) Administered to Healthy Participants and Patients With Stage 4 Renal Impairment or Stage 5 Renal Impairment Requiring Hemodialysis

NCT01833754
View directory record Official record
Conditions
Osteoporosis
Interventions
Romosozumab
Drug
Lead sponsor
Amgen
Industry
Eligibility
50 Years and older
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2014
U.S. locations
5
States / cities
Tempe, Arizona • Los Angeles, California • Denver, Colorado + 2 more
Source: ClinicalTrials.gov public record
Updated Jul 21, 2022 · Synced Sep 5, 2026, 5:25 PM EDT
Completed No phase listed Observational

An Observational Study (Registry) Assessing Treatment Outcomes and Safety for Children and Adults Who Are Prescribed Norditropin® (Human Growth Hormone)

NCT01009905
View directory record Official record
Conditions
Growth Hormone Disorder, Pituitary Dwarfism, Hypopituitarism
Interventions
somatropin
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
Up to 18 Years
Enrollment
22,960 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2016
U.S. locations
1
States / cities
Plainsboro, New Jersey
Source: ClinicalTrials.gov public record
Updated Apr 11, 2017 · Synced Sep 5, 2026, 5:25 PM EDT
Completed Phase 1 Interventional

A Phase I Study of MGCD0103 Given Three-Times Weekly In Patients With Leukemia Or Myelodysplastic Syndromes

NCT00324129
View directory record Official record
Conditions
Leukemia, Myelodysplastic Syndromes
Interventions
MGCD0103
Drug
Lead sponsor
Mirati Therapeutics Inc.
Industry
Eligibility
18 Years and older
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jan 7, 2015 · Synced Sep 5, 2026, 5:25 PM EDT
Not listed Phase 2 Interventional

Study of ALD-401 Via Intracarotid Infusion in Ischemic Stroke Subjects

NCT01273337
View directory record Official record
Conditions
Stroke, Ischemic Stroke, Stroke in Middle Cerebral Artery (MCA)
Interventions
ALD-401, Sham Procedure
Biological · Procedure
Lead sponsor
Aldagen
Industry
Eligibility
30 Years to 83 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
9
States / cities
Los Angeles, California • Miami, Florida • Minneapolis, Minnesota + 6 more
Source: ClinicalTrials.gov public record
Updated Jan 15, 2014 · Synced Sep 5, 2026, 5:25 PM EDT
Not yet recruiting Not applicable Interventional Accepts healthy volunteers

Percutaneous Cryoablation of Intercostal Nerves for the Treatment of Rib Fractures

NCT06533904
View directory record Official record
Conditions
Trauma, Rib Fractures, Chest Wall Disorder, Respiratory Insufficiency, Pain, Chest, Rib Trauma, Rib Fracture Multiple, Respiratory Failure, Respiratory Distress Syndrome
Interventions
Percutaneous Cryoablation of Intercostal Nerves, Multi-modal pain regimen
Procedure · Other
Lead sponsor
Loma Linda University
Other
Eligibility
18 Years to 80 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2028
U.S. locations
1
States / cities
Loma Linda, California
Source: ClinicalTrials.gov public record
Updated Feb 8, 2026 · Synced Sep 5, 2026, 5:25 PM EDT
Withdrawn No phase listed Observational

Bariatric Surgery Outcomes

NCT01057784
View directory record Official record
Conditions
Morbid Obesity
Interventions
Bariatric surgery.
Procedure
Lead sponsor
University of California, Los Angeles
Other
Eligibility
Not listed
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
2
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Dec 7, 2014 · Synced Sep 5, 2026, 5:25 PM EDT
Completed Phase 2 Interventional

Chemotherapy Followed by Peripheral Stem Cell Transplantation And Biological Therapy in Treating Patients With Chronic Myelogenous Leukemia

NCT00005948
View directory record Official record
Conditions
Leukemia
Interventions
aldesleukin, recombinant interferon alfa, sargramostim, busulfan, peripheral blood stem cell transplantation
Biological · Drug · Procedure
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
Up to 70 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2001
U.S. locations
2
States / cities
Denver, Colorado • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Apr 1, 2010 · Synced Sep 5, 2026, 5:25 PM EDT
Completed Phase 2 Interventional Results available

Efficacy and Safety of Simtuzumab in Adults With Primary, Post Polycythemia Vera or Post Essential Thrombocythemia Myelofibrosis

NCT01369498
View directory record Official record
Conditions
Myelofibrosis
Interventions
Simtuzumab, Ruxolitinib
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
7
States / cities
Scottsdale, Arizona • Stanford, California • St Louis, Missouri + 4 more
Source: ClinicalTrials.gov public record
Updated Jun 30, 2020 · Synced Sep 5, 2026, 5:25 PM EDT
Completed Phase 1Phase 2 Interventional

Arsenic Trioxide and Imatinib Mesylate in Treating Patients With Accelerated Phase or Blastic Phase Chronic Myelogenous Leukemia or Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia

NCT00081133
View directory record Official record
Conditions
Leukemia
Interventions
arsenic trioxide, imatinib mesylate
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2005
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 4, 2013 · Synced Sep 5, 2026, 5:25 PM EDT
Recruiting Phase 4 Interventional

Multifidus Cervicis Plane Block Vs. Sham Block For Posterior Cervical Spine Fusion Surgery

NCT05996133
View directory record Official record
Conditions
Cervical Spine Fusion
Interventions
Bupivacaine Hcl 0.25% Inj, Normal saline
Drug · Other
Lead sponsor
Hartford Hospital
Other
Eligibility
40 Years to 80 Years
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
1
States / cities
Hartford, Connecticut
Source: ClinicalTrials.gov public record
Updated Sep 4, 2025 · Synced Sep 5, 2026, 5:25 PM EDT
Completed No phase listed Observational Results available

A Study to Learn About Recifercept in Patients With Achondroplasia

NCT05659719
View directory record Official record
Conditions
Achondroplasia
Interventions
Recifercept
Other
Lead sponsor
Pfizer
Industry
Eligibility
3 Months to 10 Years
Enrollment
248 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 19, 2024 · Synced Sep 5, 2026, 5:25 PM EDT
Recruiting Phase 1 Interventional

A Phase Ib Study of Rezatapopt in Combination With Azacitidine in Patients With TP53Y220C Mutant Myeloid Malignancies (Acute Myeloid Leukemia or Myelodysplastic Syndrome)

NCT06616636
View directory record Official record
Conditions
Myelodysplastic Syndrome, Acute Myeloid Leukemia
Interventions
Azacitidine, Rezatapopt
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
2
States / cities
Tampa, Florida • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 19, 2026 · Synced Sep 5, 2026, 5:25 PM EDT
Completed Phase 3 Interventional

Low and Conventional Dose of Somatropin in Growth Hormone Deficient Adult Patients

NCT00570011
View directory record Official record
Conditions
Growth Hormone Deficiency
Interventions
Somatropin
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
112 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1997 – 1998
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Dec 10, 2007 · Synced Sep 5, 2026, 5:25 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Flu Vaccine in Preventing Influenza Infection in Healthy Volunteers and in Patients Who Have Undergone Stem Cell Transplant

NCT00964821
View directory record Official record
Conditions
Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasms, Nonmalignant Neoplasm
Interventions
trivalent influenza vaccine, Immunoenzyme technique, Laboratory biomarker analysis
Biological · Other
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years to 120 Years
Enrollment
459 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2013
U.S. locations
2
States / cities
Duarte, California • Pasadena, California
Source: ClinicalTrials.gov public record
Updated Nov 6, 2017 · Synced Sep 5, 2026, 5:25 PM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Surgeon-Initiated Bone Health Referral Pathway in Patients Undergoing Lower Extremity Arthroplasty

NCT05845021
View directory record Official record
Conditions
Osteoporosis, Arthroplasty Complications, Fragility Fracture
Interventions
Surgeon-Initiated Bone Health Referral Pathway
Combination Product
Lead sponsor
Johns Hopkins University
Other
Eligibility
50 Years and older
Enrollment
2,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2028
U.S. locations
1
States / cities
Columbia, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 13, 2025 · Synced Sep 5, 2026, 5:25 PM EDT
Active, not recruiting Not applicable Interventional

The Role of Blood Flow Restriction Therapy in Postoperative Elderly Patients With Hip Fracture

NCT04809714
View directory record Official record
Conditions
Hip Fractures, Muscle Atrophy
Interventions
Blood Flow Restriction with Delfi Tourniquet System Cuff, Routine Post-operative Physical Therapy
Device · Other
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
65 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Jan 25, 2026 · Synced Sep 5, 2026, 5:25 PM EDT
Completed Phase 2 Interventional

Parathyroid Hormone (PTH) With Alendronate for Osteoporosis

NCT00005006
View directory record Official record
Conditions
Osteoporosis
Interventions
Parathyroid Hormone, Alendronate, Teriparatide
Drug
Lead sponsor
Helen Hayes Hospital
Other
Eligibility
50 Years and older · Female only
Enrollment
140 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1987 – 2006
U.S. locations
1
States / cities
West Haverstraw, New York
Source: ClinicalTrials.gov public record
Updated Aug 18, 2015 · Synced Sep 5, 2026, 5:25 PM EDT
Completed No phase listed Observational Results available

Acromegaly Treatment Quality of Life Study

NCT01732406
View directory record Official record
Conditions
Acromegaly
Interventions
Not listed
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 75 Years
Enrollment
126 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 28, 2019 · Synced Sep 5, 2026, 5:25 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Treatment of Central Retinal Vein Occlusion Using Stem Cells Study

NCT03981549
View directory record Official record
Conditions
Central Retinal Vein Occlusion
Interventions
Autologous Bone Marrow CD34+ Stem Cells, Sham Therapy
Biological
Lead sponsor
The Emmes Company, LLC
Industry
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
1
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated Dec 1, 2024 · Synced Sep 5, 2026, 5:25 PM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Open Access Database of Standing Full Body Radiographs in Asymptomatic Volunteers

NCT03076658
View directory record Official record
Conditions
Intervertebral Disc Degeneration, Osteoarthritis, Spine
Interventions
EOS imaging
Radiation
Lead sponsor
University of Colorado, Denver
Other
Eligibility
21 Years to 85 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2031
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Sep 27, 2023 · Synced Sep 5, 2026, 5:25 PM EDT
Not listed Phase 2 Interventional

Vaccine Therapy and GM-CSF in Treating Patients With Low-Risk or Intermediate-Risk Myelodysplastic Syndrome

NCT00513578
View directory record Official record
Conditions
Myelodysplastic Syndromes
Interventions
PR1 leukemia peptide vaccine, incomplete Freund's adjuvant, sargramostim
Biological
Lead sponsor
The Vaccine Company
Industry
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2007
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jan 5, 2014 · Synced Sep 5, 2026, 5:25 PM EDT
Completed Phase 2 Interventional Results available

Azacitidine, Venetoclax, and Trametinib for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia or Higher-Risk Myelodysplastic Syndrome

NCT04487106
View directory record Official record
Conditions
Recurrent Acute Myeloid Leukemia, Recurrent Chronic Myelomonocytic Leukemia, Recurrent Myelodysplastic Syndrome, Refractory Acute Myeloid Leukemia, Refractory Chronic Myelomonocytic Leukemia, Refractory Myelodysplastic Syndrome
Interventions
Azacitidine, Trametinib, Venetoclax
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Apr 21, 2025 · Synced Sep 5, 2026, 5:25 PM EDT
Not listed No phase listed Observational Accepts healthy volunteers

Role of Cardiometabolic Risk Factors in Childhood Bone Development

NCT02355717
View directory record Official record
Conditions
Obesity, Cardiovascular Disease, Type 2 Diabetes, Osteoporosis
Interventions
Observational Study
Other
Lead sponsor
Augusta University
Other
Eligibility
9 Years to 15 Years
Enrollment
400 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2021
U.S. locations
1
States / cities
Augusta, Georgia
Source: ClinicalTrials.gov public record
Updated Nov 19, 2019 · Synced Sep 5, 2026, 5:25 PM EDT
Completed Phase 1 Interventional Results available

Vaccine Therapy and GM-CSF in Treating Patients With Acute Myeloid Leukemia, Myelodysplastic Syndromes, Non-Small Cell Lung Cancer, or Mesothelioma

NCT00398138
View directory record Official record
Conditions
Leukemia, Lung Cancer, Malignant Mesothelioma, Myelodysplastic Syndromes, Primary Peritoneal Cavity Cancer
Interventions
WT-1 analog peptide vaccine, incomplete Freund's adjuvant, sargramostim, polymerase chain reaction, flow cytometry, immunoenzyme technique
Biological · Genetic · Other
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years to 120 Years
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 1, 2016 · Synced Sep 5, 2026, 5:25 PM EDT